Overview
- Q3 revenue reached about $2.51 billion with earnings of $2.40 per share, topping analyst expectations.
- Management now targets roughly 17% to 17.5% Da Vinci procedure growth for 2025, up from prior guidance.
- The company placed 427 robotic systems in the quarter, rising from 379 a year earlier and 395 in Q2 2025.
- Executives repurchased about 4 million shares for just under $2 billion, drawing on a cash balance near $9.5 billion.
- Research cited increased after-hours use as a contributor to procedure reacceleration, even as the stock trades near 73 times earnings.